Grifols SA

1GRF

Company Profile

  • Business description

    Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

  • Contact

    Avinguda de la Generalitat, 152-158
    Parc de Negocis Can Sant Joan
    Sant Cugat del Valles
    Barcelona08174
    ESP

    T: +34 935710500

    E: [email protected]

    https://www.grifols.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    23,822

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,365.7024.700.30%
CAC 407,593.8738.000.50%
DAX 4022,496.9871.150.32%
Dow JONES (US)40,669.36141.740.35%
FTSE 1008,492.342.51-0.03%
HKSE22,119.41111.300.51%
NASDAQ17,446.3414.98-0.09%
Nikkei 22536,452.30406.921.13%
NZX 50 Index12,148.60245.292.06%
S&P 5005,569.068.230.15%
S&P/ASX 2008,145.6019.400.24%
SSE Composite Index3,279.037.62-0.23%

Market Movers